Literature DB >> 34470557

Escherichia coli as an antibody expression host for the production of diagnostic proteins: significance and expression.

Sergiu Huleani1, Michael R Roberts2, Lucy Beales3, Emmanouil H Papaioannou1.   

Abstract

This review article concerns the production of recombinant antibody fragments for applications mainly in the diagnostic sector. The so-called "point of care diagnostics" is very important for timely diagnosis and treatment, thus being able to save lives and resources. There is intense pressure for more accurate and less expensive rapid diagnostic tests, with a value preferably <$1. Thus, the large-scale cost-effective production of recombinant antibodies is vital. The importance of Escherichia coli toward the production of inexpensive rapid tests will be explained in this review paper. Details about the different strains of E. coli, the strategies used for the insertion and the expression of recombinant proteins, and the challenges that still exist are provided. Afterward, the importance of the expression scale and culture parameters in the final yield of the antibodies are examined. From this analysis, it appears that for good yields of recombinant antibodies, aside from appropriate gene transfer and expression, the culturing parameters are of paramount importance. Larger scale production is more favorable, mainly due to the higher cell densities that can be achieved. Yields of functional Fab fragments in the range of 10-20 mg/L are considered good in shake flasks, whereas in bioreactors can be up to 1-2 g/L. An amount of 10-500 mg of such antibody per million rapid tests is required. Despite the substantial importance of the production of the antibodies and their fragments, their downstream processing should be appropriately considered from the beginning for achieving the target value of the final rapid diagnostic tests.

Entities:  

Keywords:  Antibody fragments expression in E. coli; E. coli cultures; affinity tags; bioreactors; expression plasmid; periplasmic antibody fragments expression; scale-up

Mesh:

Substances:

Year:  2021        PMID: 34470557     DOI: 10.1080/07388551.2021.1967871

Source DB:  PubMed          Journal:  Crit Rev Biotechnol        ISSN: 0738-8551            Impact factor:   8.429


  4 in total

1.  Developing of specific monoclonal recombinant antibody fused to alkaline phosphatase (AP) for one-step detection of fig mosaic virus.

Authors:  Niloofar Rajabi; Mohammad Reza Safarnejad; Farshad Rakhshandehroo; Masoud Shamsbakhsh; Hodjattallah Rabbani
Journal:  3 Biotech       Date:  2022-03-07       Impact factor: 2.406

2.  PERISCOPE-Opt: Machine learning-based prediction of optimal fermentation conditions and yields of recombinant periplasmic protein expressed in Escherichia coli.

Authors:  Kulandai Arockia Rajesh Packiam; Chien Wei Ooi; Fuyi Li; Shutao Mei; Beng Ti Tey; Huey Fang Ong; Jiangning Song; Ramakrishnan Nagasundara Ramanan
Journal:  Comput Struct Biotechnol J       Date:  2022-06-03       Impact factor: 6.155

3.  Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD.

Authors:  Dustin Britton; Kamia Punia; Farbod Mahmoudinobar; Takuya Tada; Xunqing Jiang; P Douglas Renfrew; Richard Bonneau; Nathaniel R Landau; Xiang-Peng Kong; Jin Kim Montclare
Journal:  Biochem Eng J       Date:  2022-08-23       Impact factor: 4.446

Review 4.  Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.

Authors:  Md Harunur Rashid
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.